1352625-33-2

Basic information

• Product Name: 4-Fluoropyrazolo[1,5-a]pyridine-3-carboxylic acid
• Synonyms: 4-Fluoropyrazolo[1,5-a]pyridine-3-carboxylic acid
• CAS NO: 1352625-33-2
• Molecular Formula: C₈H₅FN₂O₂
• Molecular Weight: 180.1359032
• Mol File: 1352625-33-2.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.53±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -1.38±0.41(Predicted)
• CAS DataBase Reference: 4-Fluoropyrazolo[1,5-a]pyridine-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Fluoropyrazolo[1,5-a]pyridine-3-carboxylic acid(1352625-33-2)
• EPA Substance Registry System: 4-Fluoropyrazolo[1,5-a]pyridine-3-carboxylic acid(1352625-33-2)

Safety Data

• Hazardous Substances Data: 1352625-33-2(Hazardous Substances Data)

Upstream product

• 1352625-28-5 4-fluoropyrazole[1,5-a]pyridine-3-carboxylic acid ethyl ester 
• 372-47-4 3-Fluoropyridine 

Relevant articles and documents

IMIDAZO [1, 2 -A] PYRIDINE AND PYRAZOLO [1, 5 -A] PYRIDINE DERIVATIVES AS TRPV1 ANTAGONISTS

A compound of formula of formula (I) wherein A represents a single bond, a CH2 group or a CH (Me) group; X1 represents a hydrogen atom, a fluorine atom or a methyl group; X2 represents a hydrogen atom, a fluorine atom, a methyl group or a CH2OH group; X3 represents a hydrogen atom, a fluorine atom or a CH2OH group, and at least two of X1, X2 and X3 are hydrogen; Y represents a C atom and Z represents a N atom or Y represents an N atom and Z represents a C atom. R1 represents a halogen atom, a C1-4 alkyl group, a trifluoromethyl group or a trifluoromethoxy group, and R2 and R3 are each independently selected from a hydrogen atom, a halogen atom, a C1-4 alkyl group, a trifluoromethyl group or a trifluoromethoxy group. or a pharmaceutically acceptable salt or solvate thereof. salt or solvate thereof.

HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS

New heteroaryl imidazolone derivatives having the chemical structure of formula (I) disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).